Business:
Small Molecules
Drug notes:
Ziftomenib Clin1 AML, 10 efforts Clin0 AML, ALL; KO-2806 3 efforts RD/Clin0 multiple cancers
About:
Kura Oncology is using precision oncology to find cures for cancer patients. By understanding the evolving molecular processes that drive cancer, Kura is pioneering new approaches to treat diseases, including head and neck cancer, lung cancer and acute leukemias. In particular, Kura is gaining a deep understanding of the underlying causes of treatment resistance - this will enable them to design smart combination regimens with other cancer therapies to target tumors from multiple directions, improving the likelihood of success. Important to their approach, Kura is finding novel biomarkers that can be used to stratify patients through the use of precision oncology. Kura’s lead candidate, ziftomenib, is a small molecule drug that is currently being investigated in clinical trials.
Vice President, Global Program Leader Boston, Remote |18 days ago
Manager/Senior Manager, Clinical Data Sciences Boston, San Diego, Remote |21 days ago
Director, Commercial Analytics and Performance Rep... Boston, San Diego, Remote |25 days ago
Associate Director/Director, Drug Safety Operation... Boston, MA|31 days ago
Manager/Sr. Manager, IR & Corporate Communications... San Diego, CA|31 days ago
Director, Regulatory Affairs Operations Boston, MA|32 days ago
Senior Director, Corporate Communications San Diego, CA|33 days ago
Senior Clinical Trial Leader Boston, MA|38 days ago
Associate Director/Director, Clinical Pharmacology... Boston, San Diego, Remote |52 days ago